- Home
- JZ vs PIRS Comparison
JZ vs PIRS Comparison
Compare JZ & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZ
- PIRS
- Stock Information
- Founded
- JZ 2011
- PIRS 2001
- Country
- JZ China
- PIRS United States
- Employees
- JZ N/A
- PIRS N/A
- Industry
- JZ Other Consumer Services
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- JZ Real Estate
- PIRS Health Care
- Exchange
- JZ Nasdaq
- PIRS Nasdaq
- Market Cap
- JZ 21.4M
- PIRS 22.4M
- IPO Year
- JZ 2022
- PIRS N/A
- Fundamental
- Price
- JZ $1.07
- PIRS $15.89
- Analyst Decision
- JZ
- PIRS
- Analyst Count
- JZ 0
- PIRS 0
- Target Price
- JZ N/A
- PIRS N/A
- AVG Volume (30 Days)
- JZ 18.3K
- PIRS 37.6K
- Earning Date
- JZ 12-06-2024
- PIRS 11-13-2024
- Dividend Yield
- JZ N/A
- PIRS N/A
- EPS Growth
- JZ N/A
- PIRS N/A
- EPS
- JZ N/A
- PIRS N/A
- Revenue
- JZ $50,810,288.00
- PIRS $1,352,000.00
- Revenue This Year
- JZ N/A
- PIRS N/A
- Revenue Next Year
- JZ N/A
- PIRS N/A
- P/E Ratio
- JZ N/A
- PIRS N/A
- Revenue Growth
- JZ N/A
- PIRS N/A
- 52 Week Low
- JZ $0.53
- PIRS $6.20
- 52 Week High
- JZ $2.89
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- JZ 50.60
- PIRS 43.29
- Support Level
- JZ $1.06
- PIRS $15.15
- Resistance Level
- JZ $1.30
- PIRS $16.97
- Average True Range (ATR)
- JZ 0.15
- PIRS 0.72
- MACD
- JZ 0.00
- PIRS -0.08
- Stochastic Oscillator
- JZ 46.34
- PIRS 30.75
About JZ Jianzhi Education Technology Group Company Limited
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.